After 6 days of treatment with 3% DSS, we observed an increase in Beclin-1 levels, an increase in the LC3-II/I ratio, and a decrease in p62/SQSTM1 levels in IBD model mice (Fig. 3A, B). This evidence concerns the gene SQSTM1 and inflammatory bowel disease.